Table 3. Association between primary tumor sidedness and gene alterations of TK receptors/RAS pathway/PI3K pathway (N = 201).
| Primary tumor sidedness | P-value | ||
|---|---|---|---|
| Variable | Right (n = 56) | Left (n = 145) | |
| ERBB2 status | |||
| Wild-type | 54 | 132 | 0.243 |
| Mutanta | 2 | 13 | |
| MET status | |||
| Wild-type | 55 | 139 | 0.676 |
| Mutanta | 1 | 6 | |
| EGFR status | |||
| Wild-type | 56 | 141 | 0.578 |
| Mutant | 0 | 4 | |
| FGFR1 status | |||
| Wild-type | 56 | 135 | 0.065 |
| Mutant | 0 | 10 | |
| PDGFRA status | |||
| Wild-type | 55 | 144 | 0.481 |
| Mutant a | 1 | 1 | |
| KRAS status | |||
| Wild-type | 29 | 97 | 0.047 |
| Mutant | 27 | 48 | |
| NRAS status | |||
| Wild-type | 54 | 142 | 0.620 |
| Mutant | 2 | 3 | |
| HRAS status | |||
| Wild-type | 55 | 143 | 0.999 |
| Mutant | 1 | 2 | |
| BRAF status | |||
| Wild-type | 41 | 136 | < 0.001 |
| Mutant | 15 | 9 | |
| MAPK2K1 status | |||
| Wild-type | 54 | 137 | 0.729 |
| Mutant | 2 | 8 | |
| PTEN status | |||
| Wild-type | 39 | 107 | 0.554 |
| Mutant b | 17 | 38 | |
| PIK3CA status | |||
| Wild-type | 41 | 127 | 0.014 |
| Mutant | 15 | 18 | |
| Alterations in TK receptors/RAS pathway/PI3K pathway | |||
| 0 | 6 | 41 | 0.024 |
| 1 | 24 | 56 | |
| 2 or more | 26 | 48 | |
| All wild-type | 6 | 41 | 0.009 |
| Mutant-type | 50 | 104 | |
a Including mutation and amplification.
b Including mutation and deletion